{"name":"Annexon Biosciences","slug":"annexon","ticker":"ANNX","exchange":"NASDAQ","domain":"annexonbio.com","description":"Annexon Biosciences is a clinical-stage neuroscience biotech company focused on developing treatments for neurodegenerative diseases. The company's pipeline includes several promising candidates, including ANX-005, a monoclonal antibody targeting the complement system. With a strong focus on neuroscience, Annexon Biosciences is well-positioned to capitalize on the growing demand for innovative treatments in this space. As a clinical-stage company, Annexon Biosciences is still in the early stages of development, but its pipeline and therapeutic focus make it an exciting investment opportunity for those interested in the neuroscience sector.","hq":"Brisbane, CA","founded":0,"employees":"","ceo":"Douglas Love","sector":"Clinical-Stage Neuroscience Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$450M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":184698000,"netIncome":-206690000,"cash":162051000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Annexon Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Annexon Biosciences reported its fourth quarter and full year 2023 financial results, highlighting a strong cash position and progress in its pipeline.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"trial","headline":"Annexon Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ANX-005","summary":"Annexon Biosciences announced positive topline results from its Phase 1b clinical trial of ANX-005, a monoclonal antibody targeting the complement system.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPN0toQ2U2Q1BqcHBvOGdiak9kd0c0RFVwQkZ4bmJrY1BFS3dKTzBDOWlVcTMwc1FFS0lYMXhaT21keXh0cWhyRVl0eXpWdmpjZnM0VGItVmxYUF9qMkhvRTRBUmNfUUpvUDdYMm9YeU5DTERFU1VGNXJGNUkyb2dXMWNTXzBtUWdveHcwaVFvZTNKZWt1M3V6U29lRVc3YmlJMDdYYmo5VDY?oc=5","date":"2026-03-31","type":"deal","source":"GuruFocus","summary":"Annexon (ANNX) Gains Attention Amid Pharma Deal Activity - GuruFocus","headline":"Annexon (ANNX) Gains Attention Amid Pharma Deal Activity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOZEtKdFd2alB5bHNod3ZSbENTLTNoRlhCRVRabVFOR2lfa29NZVBCRFdPYkV1WDVmejN0MTVFeldzV3EtY3BjTldqNkZXb0dWLWhjRmhONDhMWnlrcl83TFlLTHg4WjhMQ0FURG9wR1BMUjZ5ME9xQkJiZVpKM1NoQmhMZGk4SDVPdHBfcnhjSWNaOTJyOUhtRlY0UHFIUzk1M3hvSnU0cERRbW03QU1oYmhoWDFEVWVmQ2M5eFh0eFhWb3V2UWlB?oc=5","date":"2026-03-31","type":"pipeline","source":"Investing.com","summary":"Jefferies reiterates Annexon Biosciences stock rating on M&A activity - Investing.com","headline":"Jefferies reiterates Annexon Biosciences stock rating on M&A activity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdGMxbWExeWhoTldjUUx6ZkMzcTlnQkUxOWVnQ2txVnhPQzQ3QXhvQXZkQ0c0amRRZFdmQ1pFV1g3eEdUMjBTcG9hal9PVTRCQ2FtVzF6Nmh1dEJHeVh4aFVrRWdzNlNTTDJNVHNMSHc3d2tJcGt5TTdWMkVDOExuVVRhMnRUNlhpVDc0T0poVzFHWUxnb0g0UmJ5Y01sSEpfeEFUYU1tX2wzcU5CbThBY2tCVmYtNFhVc18w?oc=5","date":"2026-03-30","type":"earnings","source":"Quantisnow","summary":"Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - Quantisnow","headline":"Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTFBPQUszMW5kWjB0YTRaUEZEa1NtclFVNkV3ZUVsYk5ocFctRUZfeHZUX0loWUtleU85Rl9tX1Jwd1U2TXU3WndHTV9mTE5Ldw?oc=5","date":"2026-01-16","type":"earnings","source":"Stock Titan","summary":"Latest ANNX News - Annexon Reports Fourth Quarter and Year-End... - Stock Titan","headline":"Latest ANNX News - Annexon Reports Fourth Quarter and Year-End...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNVXJOLUZOSXNodlhjNGpCSXR0bWE1SFc1eVVhVlpQMHdNQk5Rb0FHa0ZLbWpqYndWWFpKbmtMZ25fbjQwbHF4dlo0NGpRRXRoaHhkd0ZRdS1zV0VDbENfUGM4TWY2Rzl6RWhWR0tqT0MyU1IzUG5BeUFvclhQQXNBai1naU5FcWRDZWd0dkNOLWE4eThsOUlGaGFveW5MNnY3VHRpTTE4S3c3cWZPeDFFQmhmLURzOUNXNVRaSjJRbFo0aDQwdWYwcjZHUUFGTTJ1TzJ5VGtTSG84clg4REJUZ2h2bWJWYldXTUE?oc=5","date":"2026-01-07","type":"pipeline","source":"GlobeNewswire","summary":"Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire","headline":"Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNOEpzTUsyQXRCazhKNGtTU3hEY2NxREpFRndsbHRRZjJpcGk2ZzM1VURka29QVXMwT2h6QmNiSW1uUE05dTd0X2gzUmRrX3hfY0stYVJFOUg3MERaNEp1eU41WVI0WXh0N0RmSUdGN2FmTlVfSV96S3FpcWZaVEtRVHF2dWR5YUlOOXJHay1NZnlKeFNfNldjaGM2WEhNemtsTlZ6cTFjNV9qM05VM2FpMU1Qa0dJRzR2?oc=5","date":"2025-11-10","type":"pipeline","source":"Stock Titan","summary":"Annexon (NASDAQ: ANNX) on track for January 2026 GBS MAA filing; cash stands at $188.7M - Stock Titan","headline":"Annexon (NASDAQ: ANNX) on track for January 2026 GBS MAA filing; cash stands at $188.7M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOQ2tENW9pNU9FR3E0ZGxTTEticjlzV1hrejZJRl9xRDVCLTlrdi1kazFiT3ZKTnpGa1BlU0FXaENoWVVxU2FSWGs0TjFZUkdISzBVWGNKeVd0VVFON3pHRHpRdFhzVk15TEtOQkllWEZ6ZHQ4Q0s2eUtJcC1POVJvWnpoVkduaUdEQTdsYzVwQjQtQkpha3hsbXBRTW9IYUV5MUdiMmFLaXdpSTJlNXVTcWN2Uy1HQUV5ZEprWnFoc295cEhhaUE?oc=5","date":"2025-04-09","type":"pipeline","source":"Fierce Pharma","summary":"Annexon rolls out Guillain-Barré awareness campaign for HCPs amid promising results for targeted therapy - Fierce Pharma","headline":"Annexon rolls out Guillain-Barré awareness campaign for HCPs amid promising results for targeted therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOYlE1bDB1YnJCNjQ0QVBTMWdxb1ZwXzhLTFQ5ZHhEbWxWbnF1U2g1OGFydDlWYW1Pb1I2WklXdzNXZkhSSmFCUGVEX3ZWemg3VmhoSXd6WlY3X3JqZHpLYnZGY3JQWVdKOEcybWQzRHhyamFDSDJBckcxYngyd3hTS1kza0RqbXR2SVR2dnkyOGZWQ0ZXVzV0bXpzcF9UenFvRmFVQnlZU3NuaHlEcG10SHY0Z0pxOG1rdjQ2WGpSZnAxYWFFQjBENkZwNHMxc190S1dNdGE2Y3ZlZ21fVWV2OTJtX2NSaEd5Vm1nLTBpMGpsRnRnVFVHNmRNVUZ5NkhvX2pXaXlDQ0wwckEwR2c?oc=5","date":"2025-04-09","type":"pipeline","source":"Business Wire","summary":"Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire","headline":"Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Dire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxORGxyNkFvYUd2MHdvTGFMZURTZ1dFVWp5aUlHRmRFMTkza1RTVWQ1VGp1b2l4TEMxbnZhaW5uRWwxei1xRWdPU204OWZhbGNldjZ3MGF1eG9PUnVKQjlLSWdKUm9adFdITkJ0S0N0OVJnOTcyNTRaRkNUMEptLXpNdjdpSHJCcFlsVGxoWExiSHNBdmFibFZ4UnZwbW5kaElVdHpXdUxlNEMzbkJGY1VLTmVNNGR0OGlqdzlYMG5iMXllbUhVazh6bG9LanRVd1I2RE5uYVN5TFVIUDVLVUU2Y0pBVFVkdzZnTWpGRmFzc2JqVmk2cEF6ZmxyMHBqWHk5SUJUYUNEdGZPeE5mekxrM3pqdUNEZ2s?oc=5","date":"2025-03-03","type":"earnings","source":"GlobeNewswire","summary":"Annexon Reports Fourth Quarter and Year-End 2024 Financial - GlobeNewswire","headline":"Annexon Reports Fourth Quarter and Year-End 2024 Financial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQVUtzSkU0dWlZNTVsM3hvYXFkZEgxWTZyR1NOSmxpcUxlemJCMTJuTlZyN2VVcTlYZkFFa211bmRBZWZTZ3JYM0tmcXJmdXlhc1dUZlgyWkhjTU9IUGkxeHJlbmJIZ2JPcGtnd041bkk1T0YwTnp1THdVS0Fnb2ZEVlpKYlE4UmhG?oc=5","date":"2025-02-18","type":"pipeline","source":"The Pharma Letter","summary":"Duo join Nura Bio’s quest in neurological diseases - The Pharma Letter","headline":"Duo join Nura Bio’s quest in neurological diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBBU19NNjNjZVAxVU9KNUtsQ1BiNU5Gd1phYjZsV0FKMUJCRTV6Xy04bko2Rl9ZZzhWOXlYVzBmMzNObHN4N1lLQ1lPb3VTUlpo?oc=5","date":"2024-03-13","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBOZUZ4alFwZldvUTJkTW9vcFUtY0huZ0NDdVVLZDMtb2UxR3YwVnpqMFJmVUZYWGFDWmtsWGpTNjg3bmVReS1hR2hYdHV2cVcyZVZQWU9EMmZfWVhIMVh0OUVJRlRLVWV3OWYzcHhHOWJiWjFVWDdVNA?oc=5","date":"2024-03-12","type":"deal","source":"Yahoo Finance","summary":"J.P. Morgan Predicts up to 140% Rally for These 2 ‘Strong Buy’ Stocks - Yahoo Finance","headline":"J.P. Morgan Predicts up to 140% Rally for These 2 ‘Strong Buy’ Stocks","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Roche","Eli Lilly"],"therapeuticFocus":["Neurodegenerative diseases","Complement system disorders"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":184698000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-206690000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":162051000,"cashHistory":[],"totalAssets":277571000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}